

Def. Hospira's Trial Exhibit List With Cubist Objections

DTX	BegBates	EndBates	Date	Dep Ex Description	OBJECTIONS
167	CUBT0007638	CUBT0007661	10/30/2007	[REDACTED]	I
168	CUBT0007662	CUBT0007883	5/15/2007	[REDACTED]	I
169	CUBT0007884	CUBT0008061	8/23/2005	[REDACTED]	I
170	CUBT0011589	CUBT0011588	8/20/2010	[REDACTED]	NE, C
171	CUBH0536137	CUBH0536254		[REDACTED]	I
172	CUBH0360755	CUBH0360878		[REDACTED]	I
173	CUBH0303604	CUBH0303610		[REDACTED]	I
174	CUB00830537	CUB00830588	12/17/2009	[REDACTED]	I
175	N/A	N/A	7/12/2013	[REDACTED]	C, I, P
176	CUBH0535436	CUBH0535569		[REDACTED]	I
177	CUB02392076	CUB02392078	12/6/1999	F. Oleson Declaration and Power of Attorney for Patent Application	C
178	CUB00967484	CUB00967504		Redline of Bhavnani, et al., "Relationship Between Daptomycin Exposure and the Probability of a Creatine Phosphokinase Elevation as Determined in a Randomized Trial for the Therapy of Bacteremia and Endocarditis"	I, H
179	CUB02400185	CUB02400212		Redline of Bhavnani, et al., "Relationship Between Daptomycin Trough Concentration and the Probability of an Elevation in Creatine Phosphokinase as Determined in a Randomized Trial for the Therapy of Bacteremia and Endocarditis"	I, H
180	CUB02437212	CUB02437229		Oleson et al., "Once-Daily Dosing Decreases Toxicity of Daptomycin"	
181	CUB00731242	CUB00731244	1/28/1998	Fax from F. Oleson to F. LeSane Enclosing Daptomycin: Rationale for Intravenous Clinical Development	I, H
182	CUB00481019	CUB00481064	10/22/2007	[REDACTED]	I, H, C
183	CUB02230175	CUB02230176		[REDACTED] t	A-D, I, H
184	CUB00625800	CUB00625823		Eisenstein, et al., "Daptomycin: From the Mountain to the Clinic with Essential Help from Francis Tally" (Draft)	H, I, C
185	HOSP_CUB0061585	HOSP_CUB0061606	1/29/2008	Certificate of Correction re U.S. Patent RE39,071 with Request	
186	LLY00000270	LLY00000270	12/1/1987	[REDACTED]	H, I, A-A
187	LLY00000479	LLY00000482		[REDACTED]	H, I, A-A
188	CUB00146115	CUB00146228		[REDACTED]	
189	CUB00547431	CUB00547433	4/8/1997	[REDACTED]	
190	CUB00756868	CUB00756869		[REDACTED]	H, I, C

Def. Hospira's Trial Exhibit List With Cubist Objections

DTX	BegBates	EndBates	Date	Dep Ex Description	OBJECTIONS
191	CUB00826341	CUB00826352	2008	[REDACTED]	
192	CUB00914170	CUB00914197		" [REDACTED]	I, C
193	CUB01831894	CUB01832019	6/5/2006	[REDACTED]	I
194	CUB01906452	CUB01906455	2/21/2007	Jefferies & Co. Analyst Rpt., "Competitor Telavancin Did Not Get Priority Review; Positive for CBST"	I, H
195	CUB02153899	CUB02154292	7/26/2006	" [REDACTED]	I
196	CUB02229331	CUB02229332	06/2005	[REDACTED]	I
197	HOSP_CUB0162805	HOSP_CUB0162827	05/2013	Teflaro Label	
198	HOSP_CUB0162828	HOSP_CUB0162857	09/2013	Tygacil Label	
199	HOSP_CUB0162725	HOSP_CUB0162725	9/22/11	Vancomycin Label	
200	HOSP_CUB0162858	HOSP_CUB0162884	05/2013	Zyvox Label	
201	CUB02416873	CUB02416901	8/9/2006	Goldman Sachs Analyst Rpt., "Cubicin at early stages of steady ramp"	I, H
202	CUB02417088	CUB02417096	4/22/2009	Jefferies & Co. Analyst Rpt., "1Q09 EPS Beat on Light Cubicin Sales; 2009 Guidance Reaffirmed"	I, H
203	CUB02417111	CUB02417117	6/29/2007	Jefferies & Co. Analyst Rpt., "Expect Cubicin 2Q Sales to be Higher than IMS Reports; Maintain Estimates"	I, H
204	CUB02417238	CUB02417246	10/17/2008	Jefferies & Co. Analyst Rpt., "Cubicin Sales Beat Handily; Ups Guidance; Attractive Value Pay"	I, H
205	CUB02417274	CUB02417281	12/2/2005	Jefferies & Co. Analyst Rpt., "Discussion with Expert Points to Cubicin's Competitive Edges"	I, H
206	CUB02417476	CUB02417479	1/11/2010	Lazard Capital Markets Analyst Rpt., "CBST: Reports strong 4Q U.S. Cubicin sales; increasing estimates; HOLD"	I, H
207	CUB02417497	CUB02417505	1/23/2009	Lazard Capital Markets Analyst Rpt., "CBST 4Q: Increasing Cubicin estimates but we remain below consensus on EPS: HOLD"	I, H
208	CUB02417506	CUB02417513	1/24/2008	Lazard Capital Markets Analyst Rpt., "CBST: Cubicin poised for steady growth in '08 but competition looms; HOLD"	I, H
209	CUB02417736	CUB02417742	4/18/2008	Lazard Capital Markets Analyst Rpt., "CBST: Cubicin sales in line, but growth slowing; HOLD"	I, H
210	CUB02418268	CUB02418274	1/24/2006	Lazard Capital Markets Analyst Rpt., "CBST: Company remains in the red despite Cubicin's growth; HOLD"	I, H
211	CUB02419214	CUB02419225	10/30/2008	Merriman Curhan Ford Analyst Rpt., "A Unique Antibiotic with Lots of Growing Room Left; Initiating Coverage at Buy"	I, H

Def. Hospira's Trial Exhibit List With Cubist Objections

DTX	BegBates	EndBates	Date	Dep Ex Description	OBJECTIONS
212	CUB02426967	CUB02426990	3/13/2008	Thomas Weisel Partners Analyst Rpt., "IP and Competitive Headwinds Continue to Obscure Cubicin Growth; Downgrading to Market Weight"	I, H
213	CUB02427485	CUB02427513	9/14/2005	Thomas Weisel Partners Analyst Rpt., "Bacteremia / Endocarditis Label to Drive Sales"	I, H
214	CUB00198625	CUB00198723	11/18/2008	Infectious Diseases Society of America (IDSA), "Background Information on Antimicrobial Agents for Complicated Skin and Skin Structure Infections: Justification of Non-Inferiority Margins in the Absence of Placebo-Controlled Trials," for the Food and Drug Administration Anti-Infective Drugs Advisory Committee Meeting	A-D, I, H
215	CUB00151459	CUB00151495	07/2004	Infectious Diseases Society of America, Bad Bugs, No Drugs As Antibiotic Discovery Stagnates...A Public Health Crisis Brews	
216	HOSP_CUB016247 1	HOSP_CUB01624 72	4/10/2012	Decision Resources, "For the Treatment of Gram-Negative Infections, Surveyed Hospital-Based PCPs Indicate That They Are More Likely Than Infectious Disease Specialists to Prescribe Teflaro Empirically"	I, H
217	CUB02428783	CUB02428900	2010	Decision Resources Rpt: Complicated Skin and Skin Structure Infections: Recent FDA Nonapprovals Leave untapped Opportunity for Emerging Broad-Spectrum MRSA Agents	I, H
218	CUB02430970	CUB02431203	12/2009	Decision Resources Infectious Disease Study: Methicillin-Resistant Staphylococcus Aureus	I, H
219	CUBH0311209	CUBH0311379	2010	Decision Resources: Hospital Anti-Infectives: Insights on the Uptake and Formulary Inclusion of Emerging Antibiotics and Antifungals; A Survey of Infectious Disease Specialists, Internists, and P&T Committee Members	I, H
220	CUBH0567656	CUBH0567656		IMS Data (Produced in Native)	
221	CUBH0567657	CUBH0567657		IMS Data (Produced in Native)	
222	CUBH0567658	CUBH0567658		IMS Data (Produced in Native)	
223	CUBH0567659	CUBH0567659		IMS Data (Produced in Native)	
224	CUBH0567660	CUBH0567660		IMS Data (Produced in Native)	
225	CUBH0567661	CUBH0567661		IMS Data (Produced in Native)	
226	CUBH0567662	CUBH0567662		IMS Data (Produced in Native)	
227	CUBH0567663	CUBH0567663		AMR Data (Produced in Native)	
228	CUBH0567665	CUBH0567665		IMS Data (Produced in Native)	
229	CUBH0567666	CUBH0567666		IMS Data (Produced in Native)	
230	CUBH0567667	CUBH0567667		AMR Data (Produced in Native)	
231	CUBH0567668	CUBH0567668		IMS Data (Produced in Native)	

Def. Hospira's Trial Exhibit List With Cubist Objections

DTX	BegBates	EndBates	Date	Dep Ex Description	OBJECTIONS
232	HOSP_CUB016290 0	HOSP_CUB01629 00		Rausser Raw Data (Produced in Native)	C, H
233	HOSP_CUB016288 5	HOSP_CUB01628 92		[REDACTED]	D, P, NE
234	HOSP_CUB016289 3	HOSP_CUB01628 96		[REDACTED]	D, P, NE
235	HOSP_CUB016289 7	HOSP_CUB01628 97		[REDACTED]	D, P, NE
236	LLY00000406	LLY00000407	4/16/1991	[REDACTED]	H, I, A-A, C
237	HOSP_CUB016236 6	HOSP_CUB01624 70	3/1/2007	Cubist Pharmaceuticals Inc. 10-K for 2006	I
238	HOSP_CUB016236 4	HOSP_CUB01623 65	11/21/2005	Cubist Press Release, "FDA Accepts Cubicin sNDA and Grants Priority Review"	
239	HOSP_CUB016264 1	HOSP_CUB01626 59	1/15/2013	Forest Laboratories, Inc. FRX Q3 2013 Earnings Call Transcript	I, H
240	HOSP_CUB016266 7	HOSP_CUB01626 74	1/15/2010	Complaint in Pfizer et al. v. Teva (1:10-cv-00037)	I, NE, H
241	N/A	N/A	5/20/2013	Claim Construction Order	NE
242	N/A	N/A	2/15/2013	Declaration of Bruce Ganem	NE, H, I
243	CUB02181174	CUB02181182	3/11/2002	Statement of Francis P. Tally	
244	CUBH0000164	CUBH0000175	1/11/2012	Response and Amendment to 12/15/11 Office Action	C
245	LLY00010912	LLY00011337	7/18/83 - 11/15/84	[REDACTED]	R, H, A-A
246	CUB02182855	CUB02182876	11/13/2009	Request for Continued Examination and Response and Amendment	C
247	HOSP_CUB016223 0	HOSP_CUB01622 34	3/29/1989	Response to 1/18/89 Office Action	C
248	CUBH0571024	CUBH0571057	01/2013	Cubicin Package Insert	
249	CUBH0476889	CUBH0476898	02/2009	Vancomycin Package Insert	
250	N/A	N/A	2/6/2013	Cubist Objections/Responses to Hospira's RFA's (Nos. 1-204)	SUBJECT TO CUBIST'S OBJECTIONS SET FORTH IN THE DOCUMENT
251	N/A	N/A	2/15/2013	Declaration of William Gerwick	NE, H
252	N/A	N/A	9/16/2013	http://ec.europa.eu/health/authorisation-procedures-centralised_en.htm	H, A
253	CUB00180646	CUB00180667	2003	Cubicin Product Label	

Def. Hospira's Trial Exhibit List With Cubist Objections

DTX	BegBates	EndBates	Date	Dep Ex Description	OBJECTIONS
254	CUB00653158	CUB00653165	5/12/2006	[REDACTED]	
255	CUB01737320	CUB01737328	2/23/1993	Response to Final Office Action dated 11/5/92	C
256	CUB01737357	CUB01737364	11/5/1991	Amendment After Final Rejection	C
257	CUB01737400	CUB01737404	11/28/1989	Office Action Responsive to 8/28/89 Correspondence	C
258	CUB01737420	CUB01737426	11/4/1988	Response to 5/5/88 Office Action	C
259	HOSP_CUB0161336	HOSP_CUB0161340	5/1/1992	1992 FDA Guidance on Development of New Stereoisomeric Drugs	H, A, I
260	HOSP_CUB0161806	HOSP_CUB0161808	2012	http://bugsanddrugs.stanford.edu/dosing/SHCAntimicrobialDosingGuide2012.pdf	H, I, A
261	CUBH0308853	CUBH0309031	2012	[REDACTED]	
262	CUBH0309342	CUBH0309631	2012	[REDACTED]	
263	CUBH0311399	CUBH0311521	2011	Decision Resources, Antibiotic Market Opportunities Beyond the Hospital: Market Trends, Medical Practice, and Reimbursement of Outpatient Parenteral Antibiotic Therapy (OPAT)	
264	HOSP_CUB0162307	HOSP_CUB0162310	2013	Alliance for the Prudent Use of Antibiotics, Glossary, Definition for "Narrow-spectrum vs. broad-spectrum antibiotics," Available at: http://www.tufts.edu/med/apua/about_issue/glossary.shtml#narr .	H, A
265	HOSP_CUB0162729	HOSP_CUB0162732	7/23/13	Anderson, "Epidemiology of methicillin-resistant Staphylococcus aureus infection in adults," Wolters Kluwer Health, UpToDate.	H
266	CUB00848760	CUB00848768	2004	Arbeit et al., "The Safety and Efficacy of Daptomycin for the Treatment of Complicated Skin and Skin-Structure Infections", Clin. Infectious Diseases, 38:1673-81	
267	N/A	N/A	2010	Baker and Chen, Chapter 21: Enrichment and Purification of Lipopeptide Biosurfactants, Pg.281-288	
268	CUB01734253	CUB01734275	1997	Baltz, Chapter 14: Lipopeptide Antibiotics Produced by Streptomyces roseosporus and Streptomyces fradiae, Biotechnology of Antibiotics, 2d ed. pg. 415-435	
269	HOSP_CUB0055533	HOSP_CUB0055540	1997	Baltz et al, Chapter 15: Genetics of Lipopeptide Antibiotic Biosynthesis in Streptomyces fradiae A54145 and Streptomyces roseosporus A21978, Developments in Industrial Microbiology Series, pg. 93-98	
270	HOSP_CUB0004891	HOSP_CUB0004909	1994	Barclay, et al., What is the Evidence for Once-Daily Aminoglycoside Therapy? Clin. Pharmacokinetics., 27(1):32-48	

Def. Hospira's Trial Exhibit List With Cubist Objections

DTX	BegBates	EndBates	Date	Dep Ex Description	OBJECTIONS
271	HOSP_CUB016134 1	HOSP_CUB01613 47	1995	Bartizal et al, "In Vitro Evaluation of the Pneumocandin Antifungal Agent L-733560, a New Water-Soluble Hybrid of L-705589 and L-731373", Antimicrobial Agents & Chemotherapy, 39(5):1070-1076	I
272	HOSP_CUB016231 1	HOSP_CUB01623 14	7/2/2013	Baylor College of Medicine, Department of Molecular Virology and Microbiology, "Methicillin-Resistant Staphylococcus aureus (MRSA)," https://www.bcm.edu/departments/molecular-virology-andmicrobiology/index.cfm?pmid=16508 .	H, I, A
273	HOSP_CUB000493 1	HOSP_CUB00049 40	1970	Benoit et al., "Destruction and Regeneration of Skeletal Muscle after Treatment with a Local Anaesthetic, Bupivacaine (Marcaine®)," J Anat., 107(3):547-556	
274	HOSP_CUB016231 5	HOSP_CUB01623 17	11/16/2008	Berens and Armstrong, "How our hospitals unleashed a MRSA epidemic," Seattle Times	H, I, A
275	HOSP_CUB016134 8	HOSP_CUB01613 54	1976	Besson et al, "Characterization of Iturin A in Antibiotics from Various Strains of Bacillus Subtilis", J. Antibiotics, XXIX(10):1043-1049	I
276	HOSP_CUB016135 5	HOSP_CUB01613 58	1959	Bodanszky and Vigneaud, "A Method of Synthesis of Long Peptide Chains Using a Synthesis of Oxytocin as an Example," J. Am. Chem. Soc. 81:5688-691	I
277	HOSP_CUB016135 9	HOSP_CUB01613 65	1990	Boeck et al., "A54145, A New Lipopeptide Antibiotic Complex: Discovery, Taxonomy, Fermentation and HPLC," J. Antibiotics XLII(6):587-593	I
278	CUB00174378	CUB00174389	2009	Boucher et al., "Bad Bugs, No Drugs: No ESKAPE! An Update from the Infectious Diseases Society of America," Clin. Infectious Diseases 48(1):1-12	I
279	CUB00179836	CUB00179843	2007	Boucher and Sakoulas, "Perspectives on Daptomycin Resistance, with Emphasis on Resistance in Staphylococcus Aureus", Clin. Infectious Diseases, 45:601-08	
280	HOSP_CUB016231 8	HOSP_CUB01623 20	10/10/2012	BusinessWire, "Less Than a Third of Surveyed Infectious Disease Specialists and PCPs Consider Vancomycin the Preferred Antibiotic for MRSA"	I, H
281	HOSP_CUB016136 6	HOSP_CUB01613 71	1972	Carpino and Han, 9-Fluorenylmethoxycarbonyl amino-protecting group, J. Organic Chemistry, 37(22):3404-409	I
282	HOSP_CUB016137 2	HOSP_CUB01613 94	1996	Casarett And Doull's Toxicology, The Basic Science of Poisons, Fifth Edition, Chapter 2: Principles of Toxicology, pg. 13-33	I
283	HOSP_CUB016139 5	HOSP_CUB01614 10	1996	Casarett And Doull's Toxicology, The Basic Science of Poisons, Fifth Edition, Chapter 4: Risk Assessment, pg. 75-88	I
284	HOSP_CUB016215 8	HOSP_CUB01621 84	1996	Casarett And Doull's Toxicology, The Basic Science of Poisons, Fifth Edition, Chapter 5: Absorption, Distribution, and Excretion of Toxicants pg. 91-112	I

Def. Hospira's Trial Exhibit List With Cubist Objections

DTX	BegBates	EndBates	Date	Dep Ex Description	OBJECTIONS
285	HOSP_CUB016232 1	HOSP_CUB01623 28	2013	Catamaran, RxOutlook 7(4)	I
286	HOSP_CUB016141 1	HOSP_CUB01614 15	1981	Cooper et al., "Enhanced production of Surfactin from Bacillus subtilis by Continuous Product Removal and Metal Cation Additions," Appl. Environ. Microbiol., 42(3): 408-12	I
287	HOSP_CUB016232 9	HOSP_CUB01623 29	2011	Cooper and Shlaes, "Fix the antibiotics pipeline," Nature 472:32	I
288	CUBT0000701	CUBT0000702	10/8/84	Counter et al., Abstract1078, "LY146032 [N-(n-decanoyl) A21978C Nucleus] A New Acidic Lipopeptide antibiotic: Synthesis and Biological Evaluation," Program and Abstracts of the Thirty-Fourth Interscience Conference on Antimicrobial Agents and Chemotherapy, pg.281	I
289	CUB00201049	CUB00201058		Craig, "Pharmacokinetics/Pharmacodynamic Parameters: Rationale for Antibacterial Dosing of Mice and Men, State-of-the-Art Clinical Article", Clinical Infectious Diseases, 26:1-12 (1998)	I
290	HOSP_CUB000472 4	HOSP_CUB00047 30	1995	Craig, "Once-daily versus multiple-daily dosing of aminoglycosides," J Chemother. 7(Suppl 2):47-52	
291	HOSP_CUB016177 7	HOSP_CUB01617 86	2003	Darko et al., "Mississippi Mud No More: Cost-Effectiveness of Pharmacokinetic Dosage Adjustment of Vancomycin to Prevent Nephrotoxicity", Pharmacotherapy, 23:5	I
292	HOSP_CUB000475 9	HOSP_CUB00047 75	1987	Debono et al., "A21978C, a Complex of New Acidic Peptide Antibiotics: Isolation, Chemistry, and Mass Spectral Structure Elucidation," J. Antibiotics, XL(6):761-777	
293	CUB02186509	CUB02186521	1988	Debono et al, "Enzymatic and Chemical Modifications of Lipopeptide Antibiotic A21978C: The Synthesis and Evaluation of Daptomycin (LY146032)," J. Antibiotics, XLI(8):1093-1104	
294	N/A	N/A	1997	Desai and Banat, "Microbial Production of Surfactants and Their Commercial Potential," Microbiology and Molecular Biology Rvw, 61(1):47-64	
295	CUBH0474441	CUBH0474459		Diekema et al., "Survey of Infections Due to Staphylococcus Species: Frequency of Occurrence and Antimicrobial Susceptibility of Isolates Collected in the United States, Canada, Latin America, Europe, and the Western Pacific Region for the SENTRY Antimicrobial Surveillance Program, 1997-1999", Clin. Infectious Diseases, 2001:32 (Suppl. 2), pp. S114-S132	
296	HOSP_CUB016142 9	HOSP_CUB01614 42	1979	Drenckhahn, "Experimental Myopathy Induced By Amphiphilic Cationic Compounds Including Several Psychotropic Drugs," Neuroscience, 4:549-562	I

Def. Hospira's Trial Exhibit List With Cubist Objections

DTX	BegBates	EndBates	Date	Dep Ex Description	OBJECTIONS
297	HOSP_CUB016247 3	HOSP_CUB01624 77	2/20/2012	Drugs.com, "Clindamycin," http://www.drugs.com/clindamycin.html .	H, I, A
298	HOSP_CUB016247 8	HOSP_CUB01624 84	9/10/2013	Drugs.com, "Doxycycline," http://www.drugs.com/doxycycline.html .	H, I, A
299	HOSP_CUB016248 5	HOSP_CUB01624 91	3/14/2011	Drugs.com, "Minocycline," http://www.drugs.com/minocycline.html .	H, I, A
300	HOSP_CUB016249 2	HOSP_CUB01624 96	2009	Drugs.com, "Nafcillin Sodium," http://www.drugs.com/ppa/nafcillin-sodium.html .	H, I, A
301	HOSP_CUB016249 7	HOSP_CUB01625 04	12/15/2010	Drugs.com, "Oxacillin," http://www.drugs.com/mtm/oxacillin.html .	H, I, A
302	HOSP_CUB016250 5	HOSP_CUB01625 09	4/3/2012	Drugs.com, "Vancomycin," http://www.drugs.com/vancomycin.html .	H, I, A
303	HOSP_CUB016251 0	HOSP_CUB01625 12	8/14/2013	Dutton, "Biopharmas drive antibiotic development," Genetic Engineering & Biotechnology News	I, H
304	HOSP_CUB016144 3	HOSP_CUB01614 44	1953	DuVigneaud et al, "The Synthesis of an Octapeptide Amide with the Hormonal Activity of Oxytocin," J. Am. Chem. Soc. 75:4879-80	I
305	HOSP_CUB000488 1	HOSP_CUB00048 90	1990	Ebert et al. "Pharmacodynamic Properties of Antibiotics: Application to Drug Monitoring and Dosage Regimen Design", Infect. Control Hosp. Epidemiol, 11(6):319-326	
306	CUB02459414	CUB02459419	2010	Eisenstein et al., "Daptomycin: From the Mountain to the Clinic, with Essential Help from Francis Tally, MD," CID, 50(1):S10-S15	
307	HOSP_CUB016144 5	HOSP_CUB01614 47	1994	Eliel and Wilen, Stereochemistry of Organic Compounds, Wiley-Interscience at pg. 65	I, X
308	HOSP_CUB016146 7	HOSP_CUB01614 73	1990	Fakuda et al, "A54145, A New Lipopeptide Antibiotic Complex: Isolation and Characterization," J. Antibiotics XLIII(6):594-600	I
309	HOSP_CUB016251 6	HOSP_CUB01625 19	6/26/2013	FDA, "Fast track, breakthrough therapy, accelerated approval and priority review: Expediting availability of new drugs for patients with serious conditions," http://www.fda.gov/forconsumers/byaudience/forpatientadvocates/speedingaccessimportantnewtherapies/ucm128291.htm .	I
310	HOSP_CUB016273 3	HOSP_CUB01627 61	11/2011	FDA, "FY 2011 Innovative Drug Approvals," http://www.fda.gov/downloads/aboutfda/reportsmanualsforms/reports/ucm278358.pdf .	I
311	CUB01171328	CUB01171340	2006	Fowler et al., "Daptomycin Versus Standard Therapy for Bacteremia and Endocarditis Caused by Staphylococcus Aureus", N.E.J.M, 355(7):653-665	

Def. Hospira's Trial Exhibit List With Cubist Objections

DTX	BegBates	EndBates	Date	Dep Ex Description	OBJECTIONS
312	HOSP_CUB000463 9	HOSP_CUB00046 48	1997	Freeman, et al., Once-Daily Dosing of Aminoglycosides: Review and Recommendations for Clinical Practice, J.Antimicrob. Chemotherapy, 39:677-86	
313	HOSP_CUB016271 7	HOSP_CUB01627 24	7/1/2013	Freeman, Maisha Kelly, "Community-Acquired Bacterial Pneumonia: A Primer for Pharmacists," US Pharmacist	I, H, A
314	HOSP_CUB016146 5	HOSP_CUB01614 66	1966	Fridkin et al, "Use of Polymers as Chemical Reagents. I. Preparation of Peptides," J. Am. Chem. Soc., 88(13):3164-165	I
315	HOSP_CUB000475 5	HOSP_CUB00047 58		Friedland and Selwyn, Chapter 134: Infections (Excluding AIDS) in Injection Drug Users, Harrison's Principles of Internal Medicine 14 ed., pg 831-84	
316	HOSP_CUB016252 2	HOSP_CUB01625 46	2006	Grundmann et al., "Emergence and resurgence of methicillin-resistant Staphylococcus aureus as a public-health threat," The Lancet, 368(9538): 874-885.	I
317	HOSP_CUB016178 7	HOSP_CUB01617 94	2004	Grunewald et al, "Synthesis and Derivatization of Daptomycin: A Chemoenzymatic Route to Acidic Lipopeptide Antibiotics," J. Am. Chem. Soc., 126:17025-31	I
318	HOSP_CUB016147 4	HOSP_CUB01614 82	1997	Halliwell, W. H., "Cationic Amphiphilic Drug-Induced Phospholipidosis," Toxicologic Pathology, 25:53-60	I
319	CUB00180267	CUB00180269	2005	Hayden et al., "Development of Daptomycin Resistance In Vivo in Methicillin-Resistant Staphylococcus Aureus", J. Clinical Microbiol., 43(10):5285-87	I
320	HOSP_CUB016144 8	HOSP_CUB01614 64	2010	Heinzel and Verlander, Peptide Synthesis in Ullmann's Encyclopedia of Industrial Chemistry Vol. 25 pg. 411-425	I
321	HOSP_CUB016254 7	HOSP_CUB01625 49	3/19/2013	Hirschler, "Big Pharma: Few new antibiotics in the works," Chicago Tribune	I, H
322	HOSP_CUB016148 3	HOSP_CUB01614 91	1981	Hodgkinson and Lowry, "Hydrophobic-Interaction Chromatography and Anion-Exchange Chromatography in the Presence of Acetonitrile," Biochem. J. 199:619-627	
323	HOSP_CUB016255 0	HOSP_CUB01625 50	06/2010	Jancin, "Majority of MRSA Is Now Community Acquired," Pediatric News	I, H
324	HOSP_CUB016251 3	HOSP_CUB01625 15	8/15/13	Jancin, "Think 'ceftaroline' in suspected drug-resistant CAP," Family Practice News	I, H
325	CUB02009047	CUB02009076	2004	Jeu et al., "Daptomycin: A Cyclic Lipopeptide Antimicrobial Agent", Clinical Therapeutics, 26(11):1728-1757	I
326	HOSP_CUB016149 2	HOSP_CUB01615 00	1995	Kajimura et al., "Bacillopeptins, New Cyclic Lipopeptide Antibiotics from Bacillus subtilis FR-2," J. Antibiotics, 48(10): 1095-1103	I

Def. Hospira's Trial Exhibit List With Cubist Objections

DTX	BegBates	EndBates	Date	Dep Ex Description	OBJECTIONS
327	HOSP_CUB016252 0	HOSP_CUB01625 21	10/19/2004	Kanapaux, W., "Eli Lilly sells Vancocin to ViroPharma for \$116 million plus royalties," FirstWord Pharma	I, H
328	HOSP_CUB016150 1	HOSP_CUB01615 12	1986	Kennedy et al., "Multimodal Liquid Chromatography Columns for the Separation of Proteins in Either the Anion-Exchange or Hydrophobic-Interaction Mode," J. Chromatography, 359:73-84	I
329	HOSP_CUB016151 3	HOSP_CUB01615 17	2011	Khoury et al., "Proteome-wide Post-translational Modification Statistics: Frequency Analysis and Curation of the Swiss-Prot Database," Scientific Reports	I
330	HOSP_CUB016179 5	HOSP_CUB01617 99	1965	Kim and Cocolas, "Glutamic Acid Analogs: The Synthesis of 3-Alkylglutamic Acids and 4-Alkylpyroglutamic Acids," 8:509-513	I
331	HOSP_CUB010891 3	HOSP_CUB01089 20	1989	Kirsch et al., "Kinetics of the Aspartyl Transpeptidation of Daptomycin, a Novel Lipopeptide Antibiotic," Pharmaceutical Research 6(5):387-393	
332	HOSP_CUB016151 8	HOSP_CUB01615 20	1995	Koshino et al., "A New Cyclic Lipopeptide Antibiotic, Enamidonin," J. Antibiotics, 48(2):185-187	I
333	HOSP_CUB005847 2	HOSP_CUB00584 78	1998	Lakey and Ptak, "Fluorescence Indicates a Calcium-Dependent Interaction between the Lipopeptide Antibiotic LY146032 and Phospholipid Membranes," Biochemistry, 27(13):4639-4645	I
334	HOSP_CUB016255 1	HOSP_CUB01625 53	4/22/2013	Laidman, "Despite Growing Crisis, Few New Antibiotics Are in Pipeline," Medscape	I, H, A
335	CUBH0570633	CUBH0570640	2013	Lam et al., "Total Synthesis of Daptomycin by Cyclization via a Chemoselective Serine Ligation," J. American Chemical Society, 135:6272-6279	
336	HOSP_CUB016177 1	HOSP_CUB01617 76	1990	Laska et al., "In Vitro Correlation of Ultrastructural Morphology and Creatine Phosphokinase Release in L6 Skeletal Muscle Cells After Exposure to Parenteral Antibiotics," In Vitro Cell. Dev. Biol., 26:393-398	I
337	HOSP_CUB016255 6	HOSP_CUB01625 60	12/4/2012	Ledford, "FDA under pressure to relax drug rules," Nature	I, H
338	HOSP_CUB016256 1	HOSP_CUB01625 73	2005	Lee et al., "Antimicrobial Management of Complicated Skin and Skin Structure Infections in the Era of Emerging Resistance," Surgical Infections, 6(3):283-295	I
339	HOSP_CUB000466 5	HOSP_CUB00046 68	1991	Lee et al, Abstract 885: Daptomycin versus Conventional Therapy in the Treatment of Endocarditis (E) and Bacteremia, Program and Abstracts of the Thirty-First Interscience Conference on Antimicrobial Agents and Chemotherapy, 246	
340	CUB00057565	CUB00057568	1991	Lee et al, "Effect of Protein Binding of Daptomycin on MIC and Antibacterial Activity," Antimicrobial Agents and Chemotherapy, 35(12):2505-8	I

Def. Hospira's Trial Exhibit List With Cubist Objections

DTX	BegBates	EndBates	Date	Dep Ex Description	OBJECTIONS
341	HOSP_CUB016152 1	HOSP_CUB01615 22	1987	Leggett et al, "Pharmacodynamic and Pharmacokinetic Parameters (PKPs) Affecting Activity of LY 146032 Against Staphylococcus Aureus," Abstracts of the ICAAC, Abstract No. 154	
342	HOSP_CUB016257 4	HOSP_CUB01626 22	1987	Levin et al., "Appropriating the Returns from Industrial Research and Development," Brookings Papers on Economic Activity, Pg. 783-831.	I
343	HOSP_CUB016276 2	HOSP_CUB01627 96	2002	Lewis and Cody, "Unscrambling the Egg: Pre-Suit Infringement Investigations of Process and Method Patents," Journal of the Patent and Trademark Office Society, 84(1):5-37.	I
344	HOSP_CUB016152 3	HOSP_CUB01615 30	1994	Lin et al., "Structural and Immunological Characterization of a Biosurfactant Produced by Bacillus licheniformis JF-2," Appl. Environ. Microbiol. 60(1):31-38	I
345	CUB02167841	CUB02167844	1997	Lin and Jiang, "Recovery and Purification of the Lipopeptide Biosurfactant of Bacillus subtilis by Ultrafiltration," Biotech. Techniques, 11(6):413-416	
346	CUBH0570737	CUBH0570774	2011	Liu et al., IDSA Guidelines: Clinical Practice Guidelines by the Infectious Diseases Society of America for the Treatment of Methicillin-Resistant Staphylococcus Aureus Infections in Adults and Children, Clin. Infectious Diseases, 52:1-38	
347			1998	Londo et al., "Accelerated Recombinant Protein Purification Process Development Automated, Robotics-based Integration of Chromatographic Purification and Analysis," J. Chromatography, 798:73-82	U, I, H
348	HOSP_CUB016153 1	HOSP_CUB01615 33	1995	Loudon, Organic Chemistry, Third Edition, Benjamin/Cummings at pg. 243	I, X
349	HOSP_CUB016218 5	HOSP_CUB01621 94	7/23/2013	Lowy, Vancomycin-intermediate and vancomycin-resistant Staphylococcus aureus infections, Wolter Kluwer	
350	HOSP_CUB016153 4	HOSP_CUB01615 54	1970	Macdonald and Engel, "Experimental Chloroquine Myopathy," J. Neuropath Exp Neurol. 29(3):479-499	I
351	CUB00174545	CUB00174547	2006	Marty et al., "Emergence of Clinical Daptomycin Resistant Staphylococcus Aureus Isolate During Treatment of Methicillin-Resistant Staphylococcus Aureus Bacteremia and Osteomyelitis", J. Clinical Microbiol., 44(2):595-97	I
352	HOSP_CUB016262 3	HOSP_CUB01626 32	10/2010	MassHealth, "Average cost of therapy of IV antibiotics with activity against MRSA and VRE infections," Prescriber e-Letter	I, H
353	HOSP_CUB016155 5	HOSP_CUB01615 72	1982	Mastaglia, Adverse Effects of Drugs on Muscle, Drugs 24:304-321	I

Def. Hospira's Trial Exhibit List With Cubist Objections

DTX	BegBates	EndBates	Date	Dep Ex Description	OBJECTIONS
354	HOSP_CUB016157 3	HOSP_CUB01615 79	1995	McBrien et al, "Rakicidins, New Cytotoxic Lipopeptides from Micromonospora sp. Fermentation, Isolation and Characterization," J. Antibiotics, 48(12):1446-1452	I
355	HOSP_CUB000494 1	HOSP_CUB00049 64	1998	McKindley and Maderazo, Chapter 41: Drug Use in the Critically Ill Patient with Renal Dysfunction-Application of the DREM System, in Infectious Diseases in Critical Care Medicine	
356	HOSP_CUB016263 3	HOSP_CUB01626 34	4/20/2012	MedicineNet.com, "Staph Infection (Staphylococcus aureus)," http://www.medicinenet.com/staph_infection/article.htm .	I, H
357	HOSP_CUB016279 7	HOSP_CUB01628 02	2004	Meka and Gold, "Antimicrobial Resistance to Linezolid," Clin. Infectious Diseases, 39:1010-1015 (2004)	I
358	HOSP_CUB016158 0	HOSP_CUB01615 85	1963	Merrifield, "Solid Phase Peptide Synthesis. I. The Synthesis of a Tetrapeptide," J. Am. Chem. Soc. 85:2149-2154	I
359	CUB01737480	CUB01737496	2005	Miao et al., "Daptomycin biosynthesis in Streptomyces roseosporus: cloning and analysis of the gene cluster and revision of peptide stereochemistry," Microbiology 151:1507-23	
360	HOSP_CUB016158 6	HOSP_CUB01615 92	2000	Mikkola et al, "Toxic Lactonic Lipopeptide from Food Poisoning Isolates of Bacillus Licheniformis," Eur. J. Biochem., 267:4068-4074	I
361	HOSP_CUB016159 3	HOSP_CUB01616 00	1998	Miller et al., "Ecomycins, Unique Antibiotics from Pseudomonas Viridiflava," J. Appl. Microbiol., 84:937-944	I
362	HOSP_CUB016263 5	HOSP_CUB01626 40	2010	Moellering, R.C., "The problem of complicated skin and skin structure infections: the need for new agents." J. Antimicrobial Chemotherapy, 65(4):iv3-8	I
363	CUB02003372	CUB02003373	2006	Moellering, "Vancomycin: A 50-Year Reassessment," Clinical Infectious Diseases, 42(Supp1):S3-S4	
364	HOSP_CUB000466 9	HOSP_CUB00046 71	1986	Molecular Cell Biology, Chapter 3: 53 (ed. by J. Darnell, H. Lodish, and D. Baltimore, Scientific American Books, Inc., New York).	I, X
365	HOSP_CUB016160 1	HOSP_CUB01616 08	1993	Morikawa et al., "A New Lipopeptide Biosurfactant Produced by Arthrobacter sp Strain MIS38," J. Bacteriology 175(20):6459-6466	I
366	HOSP_CUB016180 0	HOSP_CUB01618 01	1955	Morrison, "Preparation of β -Methylglutamic Acid," 77:6072-6073	I
367	HOSP_CUB016160 9	HOSP_CUB01616 11	1973	Morrison and Boyd, Organic Chemistry, Third Edition, Allyn & Bacon (1973) at p. 135	I
368	HOSP_CUB016161 2	HOSP_CUB01616 19	2001	Moyne et al., "Bacillomycin D: an iturin with antifungal activity against Aspergillus Flavus," J. Appl. Microbiol., 90:622-29	I

Def. Hospira's Trial Exhibit List With Cubist Objections

DTX	BegBates	EndBates	Date	Dep Ex Description	OBJECTIONS
369	HOSP_CUB016162 0	HOSP_CUB01616 27	1997	Mühlrad et al., "Isolation, Structure Elucidation, and Synthesis of a Macrophage Stimulatory Lipopeptide from Mycoplasma Fermentans Acting at Picomolar Concentration," J. Exp. Med. 1951-1958	I
370	CUBH0570836	CUBH0570842	1990	Mulligan and Gibbs, Recovery of Biosurfactants by Ultrafiltration, J. Chem. Tech. Biotech., 47:23-29	I
371	HOSP_CUB000506 6	HOSP_CUB00051 12	1995	Mutschler et al., Chapter 2: Pharmacokinetics in Drug Actions: Basic Principles and Therapeutic Aspects. Medpharm Scientific Publishers, Stuttgart, Germany Pg. 5-47	
372	HOSP_CUB016176 3	HOSP_CUB01617 70	1998	Nakahara et al., "Myopathy Induced by HMG-CoA Reductase Inhibitors in Rabbits: A Pathological, Electrophysiological, and Biochemical Study," Toxicology and Applied Pharmacology, 152:99-106	I
373	HOSP_CUB016266 3	HOSP_CUB01626 64	4/30/2012	National Institute of Allergy and Infectious Disease, "Antimicrobial (Drug) Resistance: Gramnegative Bacteria"	I, H
374	HOSP_CUB016162 8	HOSP_CUB01616 35	1996	Neuvonen et al. "Itraconazole drastically increases plasma concentrations of lovastatin and lovastatin acid," Clin. Pharmacol Ther. 60(1):54-61	I
375	HOSP_CUB016266 1	HOSP_CUB01626 62	10/28/2013	News Medical, "MRSA musculoskeletal infections increasing among children."	I, H
376	HOSP_CUB016163 6	HOSP_CUB01616 42	1988	Numata et al., "Enzymatic Formation of Glidobactamine: A Peptide Nucleus of Glidobactins A, B and C, New Lipopeptide Antitumor Antibiotics," J. Antibiotics, XLI(10):1351-1357	I
377	HOSP_CUB016164 3	HOSP_CUB01616 48	1968	Ondetti et al., "The Synthesis of Secretin. III. The Fragment-Condensation Approach," J. Am. Chem. Soc. 90:4711-716	I
378	HOSP_CUB016164 9	HOSP_CUB01616 58	1998	Osman et al., Tuning Micelles of a Bioactive Heptapeptide Biosurfactant via Extrinsically Induced Conformation Transition of Surfactin Assembly, J. Peptide Sci., 4:449-458	
379	HOSP_CUB016255 4	HOSP_CUB01625 55	5/31/2012	Packel, Dan, "Pfizer, Teva Reach Licensing Deal For Generic Zyvox," http://www.law360.com/articles/345563/pfizer-teva-reach-licensing-deal-for-genericzyvox .	I, H
380	HOSP_CUB016165 9	HOSP_CUB01616 64	1991	Peypoux et al., "Isolation and Characterization of a New Variant of Surfactin, the [Val7] Surfactin," Eur. J. Biochem. 202:101-106	I
381	HOSP_CUB016166 5	HOSP_CUB01616 75	1999	Peypoux et al., "Recent trends in the biochemistry of surfactin," Appl. Microbiol. Biotechnol., 51:553-563	I
382	CUB02390233	CUB02390247	1983	Powell et al., "Once-daily vs. Continuous Aminoglycoside Dosing: Efficacy and Toxicity in Animal and Clinical Studies of Gentamicin, Netilmicin, and Tobramycin," J. Infect. Diseases, 147(5):918-932	I

Def. Hospira's Trial Exhibit List With Cubist Objections

DTX	BegBates	EndBates	Date	Dep Ex Description	OBJECTIONS
383	HOSP_CUB016267 5	HOSP_CUB01626 75	06/2006	Primaris Healthcare Business Solutions, "Antibiotic Recommendations for the Initial Treatment of Pneumonia," MO-06-24 HOSP-GEN	I
384	HOSP_CUB016267 6	HOSP_CUB01626 78	3/19/07	Pringle, Evelyn, "FDA hounded over Ketek scandal," LawyersandSettlements.com	I, H
385	HOSP_CUB000496 5	HOSP_CUB00050 17	1998	Protein Purification: Principles, High Resolution Methods, and Applications (J. Janson and L. Ryden, eds., John Wiley & Sons, Inc.)	
386	HOSP_CUB016267 9	HOSP_CUB01626 80		PubChem, "tigecycline – Compound Summary," http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=54686904 .	I, H
387	HOSP_CUB016268 1	HOSP_CUB01626 82	2006	PubMed, "Telavancin: TD 6424, TD-6424," http://www.ncbi.nlm.nih.gov/pubmed/17073522 .	I, H
388	HOSP_CUB016268 3	HOSP_CUB01626 85	5/22/2009	Rapaport, "Antibiotic's \$1 Billion Success May Spur Cubist Buy (Update2)"	I, H
389	HOSP_CUB000491 0	HOSP_CUB00049 30	1995	"Remington: The Science and Practice of Pharmacy," (Alfonso Gennaro ed., Mack Publishing Co.	
390	HOSP_CUB016167 7	HOSP_CUB01616 85	1999	Rinnová et al., "Solid-phase Peptide Synthesis by Fragment Condensation: Coupling in Swelling Volume," Letters in Peptide Science, 6:15-22	I
391	HOSP_CUB016180 2	HOSP_CUB01618 03	1955	Rivard and Carter, "Chemical Preparation of L-Ornithine From L-Arginine," 77:1260-1261	I
392	HOSP_CUB000463 0	HOSP_CUB00046 38	1988	Rotschafer et al., "Therapeutic Update on Glycopeptide and Lipopeptide Antibiotics," Pharmacotherapy, 8(4):211-219	
393	CUB02402252	CUB02402268	2009	Rybak et al., Therapeutic Monitoring of Vancomycin in Adult Patients: A Consensus Review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists, Am. J. Health-Syst. Pharm., 66:82-98	I
394	CUB02157009	CUB02157016	2008	Sakoulas and Moellering, Increasing Antibiotic Resistance Among Methicillin-Resistant Staphylococcus aureus Strains, Clin. Infectious Diseases, 46(Suppl. 5):S360-S367	
395	HOSP_CUB016280 3	HOSP_CUB01628 04	09/2009	Sakoulas, et al., "Clinical outcomes of patients receiving daptomycin for the treatment of Staphylococcus aureus infections and assessment of clinical factors for daptomycin failure: A retrospective cohort study utilizing the Cubicin® Outcomes Registry and Experience," Clinical Therapeutics, 31(9) (Abstract)	I, H
396	HOSP_CUB016180 4	HOSP_CUB01618 05	1988	Salituro and McDonald, "Facile Synthesis of L-Kynurenine," J. Org. Chem., 53:6138-6139	I

Def. Hospira's Trial Exhibit List With Cubist Objections

DTX	BegBates	EndBates	Date	Dep Ex Description	OBJECTIONS
397	HOSP_CUB016168 6	HOSP_CUB01616 90	1989	Schwartz et al., "L-671,329, A New Antifungal Agent I. Fermentation and Isolation," J. Antibiotics, XLII(2):163-167	I
398	HOSP_CUB016169 1	HOSP_CUB01616 93	1963	Schwyzer and Sieber, "Biochemistry Total Synthesis of Adrenocorticotrophic Hormone," Nature 199:172-174	I
399	HOSP_CUB000466 2	HOSP_CUB00046 64	1988	Sexton et al., "The Use of Daptomycin, a Lipopeptide Antibiotic, in the Treatment of Gram Positive Infections in Man," Program and Abstracts of the Twenty-Eighth Interscience Conference on Antimicrobial Agents and Chemotherapy, 275	
400	HOSP_CUB000485 0	HOSP_CUB00048 80	1989	Shaw, Chapter 4: Liquid-Gas and Liquid-Liquid Interfaces, Introduction to Colloid and Surface Chemistry, 64-114	I
401	HOSP_CUB016268 6	HOSP_CUB01626 93	2010	Shlaes, Antibiotics: The Perfect Storm, Springer Science+Business.	I
402	HOSP_CUB016269 4	HOSP_CUB01626 98	5/10/2012	Shlaes, "FDA reboot!", http://antibiotics-theperfectstorm.blogspot.com .	I, H
403	HOSP_CUB016269 9	HOSP_CUB01627 02	2013	Shlaes et al., "The FDA Reboot of Antibiotic Development," Antimicrobial Agents and Chemotherapy, 57(10):4605-607.	I
404	HOSP_CUB016169 4	HOSP_CUB01617 12	1998	Shu, "Recent Natural Products Based Drug Development: A Pharmaceutical Industry Perspective," J. Nat. Prod., 61:1053-1071	I
405	HOSP_CUB016171 3	HOSP_CUB01617 17	1968	Sieber et al, 234: Menschliches Calcitonin. IV). Die Synthese von Calcitonin M, Helv. Chim. Acta 51(8):2057-061	I
406	CUB02330956	CUB02330962	2008	Sievert, et al., "Vancomycin-Resistant Staphylococcus aureus in the United States, 2002-2006." Clin Infect Dis.,46:668-674.	
407	CUB02459705	CUB02459713	1999	Smith et al., "Emergence of Vancomycin Resistance in Staphylococcus Aureus", N.E.J.M, 340:7, 493-501	
408	HOSP_CUB016270 3	HOSP_CUB01627 06	2013	Spellberg, "New antibiotic development: Barriers and opportunities in 2012," Alliance for the Prudent Use of Antibiotics Newsletter, 30(1).	I
409	CUBH0152312	CUBH0152346	2005	Stevens et al., "IDSA Guidelines: Practice Guidelines for the Diagnosis and Management of Skin and Soft Tissue Infections", Clin. Infectious Diseases, 41:1373-1406	
410	HOSP_CUB016266 0	HOSP_CUB01626 60	9/22/1999	Stolberg, "Drug Agency Approves Antibiotic," The New York Times	I, H
411	CUB02189882	CUB02189885	1977	Sweadner et al., "Filtration Removal of Endotoxin (Pyrogens) in Solution in Different States of Aggregation," Applied & Env'tl. Microbiology, 34(4):382-385	
412	CUB00563917	CUB00563932	1999	Tally et al., "Daptomycin: a Novel Agent for Gram-Positive Infections," Exp. Opin. Invest. Drugs, 8(8):1223-1238	

Def. Hospira's Trial Exhibit List With Cubist Objections

DTX	BegBates	EndBates	Date	Dep Ex Description	OBJECTIONS
413	HOSP_CUB008867 8	HOSP_CUB00886 81	2000	Tally and DeBruin, "Development of Daptomycin for Gram-Positive Infections," J. Antimicrob. Chemotherapy 46:523-526	
414	HOSP_CUB016270 7	HOSP_CUB01627 08	01/2004	Tedesco, et al., "Daptomycin," Pharmacotherapy 24(1) (Abstract)	I, H
415	CUB01093365	CUB01093386	2004	Tice et al., IDSA Guidelines: Practice Guidelines for Outpatient Parenteral Antimicrobial Therapy, Clin. Infectious Diseases, 38:1651-72	I
416	HOSP_CUB016270 9	HOSP_CUB01627 12		Todar, K., "Antimicrobial Agents in the Treatment of Infectious Disease," Todar's Online Textbook of Bacteriology	I
417	HOSP_CUB016271 3	HOSP_CUB01627 15		UCSF Infectious Diseases Management Program, Daptomycin Monograph, Available at: http://clinicalpharmacy.ucsf.edu/idmp/whatsnew/dapto_monograph.htm .	I, H
418	HOSP_CUB016271 6	HOSP_CUB01627 16		UNeMed website, Chart "Systemic Antibiotics approved by FDA, 1980-2012," http://www.unemed.com/wpcontent/uploads/2013/06/antibioticsFDAapprvd.pdf .	I, H
419	HOSP_CUB016272 6	HOSP_CUB01627 28	8/24/12	Vastag, Brian, "NIH superbug outbreak highlights lack of new antibiotics," Washington Post	I, H
420	HOSP_CUB016171 8	HOSP_CUB01617 25	2007	Verlander, "Industrial Applications of Solid-Phase Peptide Synthesis: A Status Report", Int. J. Peptide Res. Therapeutics, 13:75-82	I
421	HOSP_CUB016172 6	HOSP_CUB01617 37	2000	Vértesy et al., "Frulimicins: Novel Lipopeptide Antibiotics with Peptidoglycan Synthesis Inhibiting Activity from Actinoplanes Friuliensis sp. nov.," J. Antibiotics, 53(8):816-827	I
422	CUB00180296	CUB00180299	2005	Vikram et al., Clinical Progression of Methicillin-Resistant Staphylococcus Aureus Vertebral Osteomyelitis Associated with Reduced Susceptibility to Daptomycin, J. Clinical Microbiol., 43(10):5384-87	I
423	CUB00059522	CUB00059526	1994	Voorn "Role of Tolerance in Treatment and Prophylaxis of Experimental Staphylococcus aureus Endocarditis with Vancomycin, Teicoplanin, and Daptomycin," Antimicrobial Agents and Chemotherapy 38(3):487-493	I
424	HOSP_CUB016173 8	HOSP_CUB01617 41	1989	Watkins, J.R. et al. "Drug-Induced Myopathy in Beagle Dogs," Toxicol. Pathology, 17(3):545-548	I
425	HOSP_CUB016174 2	HOSP_CUB01617 42	1966	Wieland and Birr, "Synthesis of Peptides by Means of Activated Units Bound to Resins" Angew. Chem. Int., Edit., 5:310	I
426	HOSP_CUB016174 3	HOSP_CUB01617 50	1987	Williams, et al. "An in vitro Model for Assessing Muscle Irritation Due to Parenteral Antibiotics," Fundamental and Applied Toxicology, 9:10-17	I

Def. Hospira's Trial Exhibit List With Cubist Objections

DTX	BegBates	EndBates	Date	Dep Ex Description	OBJECTIONS
427	HOSP CUB000480 1	HOSP CUB00048 08	1992	Woodworth, et al., Single-Dose Pharmacokinetics and Antibacterial Activity of Daptomycin, a New Lipopeptide Antibiotic, in Healthy Volunteers, Antimicro. Agents & Chemo., 36(2):318-325	
428	HOSP CUB016175 1	HOSP CUB01617 59	1967	Wünsch, "Die Totalsynthese des Pankreas-Hormons Glucagon," Zeitschrift Für Naturforschung, B22:1269-1276	I
429	CUB02189854	CUB02189861	1995	Yakimov et al., "Characterization of a New Lipopeptide Surfactant Produced by Thermotolerant and Halotolerant Subsurface Bacillus Licheniformis BAS50," Appl. Environ. Microbiol., 61(5):1706-1713	I
430	CUB02460017	CUB02460024	2010	Yang, et al., "Hospital policies and practices on prevention and treatment of infections caused by methicillin-resistant Staphylococcus aureus," Am. J. of Health-System Pharmacists 67:1017-024	
431	HOSP_CUB016176 0	HOSP_CUB01617 62	1993	Yoshiyama et al. "Influence of Circadian-Stage-dependent Dosing Schedule on Nephrotoxicity and Pharmacokinetics of Isepamicin in rats," Antimicrobial Agents and Chemotherapy, 37(9):2042-43	I
432	N/A	N/A	9/16/2013	Expert Report of Simon Baker w/ Exhibits A-B	NE, H
433	N/A	N/A	11/15/2013	Reply Expert Report of Simon Baker w/ Exhibit A	NE, H
434	N/A	N/A	9/16/2013	Expert Report of Steven C. Ebert w/ Exhibits A-B	NE, H
435	N/A	N/A	11/15/2013	Reply Expert Report of Steven C. Ebert w/ Exhibit A	NE, H
436	N/A	N/A	9/16/2013	Expert Report of Bruce Ganem w/ Exhibits A-B	NE, H
437	N/A	N/A	11/15/2013	Reply Expert Report of Bruce Ganem w/ Exhibit A	NE, H
438	N/A	N/A	11/15/2013	Rebuttal Expert Report of Pranatharthi Chandrasekar w/ Exhibits A-B	NE, H
439	N/A	N/A	11/15/2013	Expert Report of Gordon Rausser w/ Exhibits A-C	NE, H
440	N/A	N/A	10/28/2013	Expert Report of Ernst R. Berndt w/ Exhibits 1-3	NE, H
441	N/A	N/A	10/28/2013	Rebuttal Expert Report of William H. Gerwick w/ Exhibits A-C	NE, H
442	N/A	N/A	10/28/2013	Expert Report of B. Joseph Guglielmo w/ Exhibits A-B	NE, H
443	N/A	N/A	10/28/2013	Rebuttal Expert Report of Allan Myerson w/ Exhibits A-C	NE, H
444	N/A	N/A		Schnellmann, Chapter 14 Toxic Responses of the Kidney (Pg. 491-514)	I, A-D, X, U
445	N/A	N/A	7/1/1980	Excerpt from The United States Pharmacopeia Twentieth Revision (Pg. 902-903, 1438)	U, I, P
446	N/A	N/A	4/1/00	21 C.F.R. 610.13 Purity (pg 63-64)	NE
447	N/A	N/A	1986	21 C.F.R. 610.13 Purity (pg 51-52)	NE
448	N/A	N/A	2/1/13	Joint Claim Construction Charts for the Patent being Asserted by Cubist	NE
449	N/A	N/A	12/17/12	Pltf Objections/Responses to Hospira's 1st Set of Roggs (Nos. 1-10)	NE
450	N/A	N/A	11/26/12	Def. Hospira's Preliminary Invalidity Contentions	NE

Def. Hospira's Trial Exhibit List With Cubist Objections

DTX	BegBates	EndBates	Date	Dep Ex Description	OBJECTIONS
451	N/A	N/A	8/24/12	Pltf Initial Disclosures Pursuant to District of Delaware Default Standard Paragraphs 3, 4(a)	NE
452	CUB00000102	CUB00000131	11/15/88	[REDACTED]	
453	CUB00563235	CUB00563484	06/1991	[REDACTED]	
454	CUB00561954	CUB00562385	10/24/1990	IND 27627 Vol. 24	H, A-A, R-MULTIPLE DOCUMENTS
455	CUB00562620	CUB00562656		[REDACTED]	
456	CUB00562657	CUB00563085	8/19/1991	[REDACTED]	
457	CUB00563086	CUB00563087	12/17/1992	[REDACTED]	
458	CUB00563088	CUB00563169	06/1992	[REDACTED]	
459	CUB00563170	CUB00563234	07/1992	[REDACTED]	
460	CUB01828487	CUB01828675	3/20/1989	[REDACTED]	
461	CUB02188059	CUB02188059	3/8/1991	[REDACTED]	
462	CUB02334981	CUB02335785	7/18/1988	[REDACTED]	
463	CUBT0000107	CUBT0000114	4/7/2000	Reissue Application, Declaration, and Power of Attorney re U.S. Patent 5,912,226	C
464	CUBT0000139	CUBT0000184		Molloy et al., "Structure of Anhydro-Daptomycin and ISO-Daptomycin," Abstract	A-A, L, H
465	CUBT0000187	CUBT0000189		Appendix D; Analytical Characterization Report	I, H, A-A, X
466	CUBT0000190	CUBT0000190	5/2/1986	[REDACTED]	H, A-A
467	CUBT0000198	CUBT0000199	8/26/1999	[REDACTED]	I, H

Def. Hospira's Trial Exhibit List With Cubist Objections

DTX	BegBates	EndBates	Date	Dep Ex Description	OBJECTIONS
468	CUBT0000327	CUBT0000328	2/4/1999	[REDACTED]	I, H, A-A
469	CUBT0000329	CUBT0000329		[REDACTED]	I, H, A-A
470	CUBT0000330	CUBT0000331	7/29/1999	[REDACTED]	I, H
471	CUBT0000385	CUBT0000402	01/2004	Tedesco and Rybak, "Daptomycin," Pharmacotherapy, 24(1):41-57	I
472	CUBT0000403	CUBT0000410	3/1/2002	Thorne and Alder, "Daptomycin: A Novel Lipopeptide Antibiotic," Clinical Microbiology Newsletter, pg 1-8	I
473	CUBT0000200	CUBT0000223		Sakoulas et al., "Evaluation of Daptomycin in Experimental Endocarditis Due to Methicillin-Resistant Staphylococcus Aureus" Abstract	
474	CUBT0000224	CUBT0000248	2005	Baltz et al., "Natural Products to drugs: Daptomycin and related lipopeptide antibiotics," Nat. Prod. Rep., 22:717-741	
475	CUBT0000271	CUBT0000287	4/5/2006	EP 1 115 417 B1	I
476	CUBT0000291	CUBT0000291		Black et al., "Preliminary Pharmacology and Pharmacokinetics of LY146032, A New Peptolipide Antibiotic," Abstract 894	I
477	CUB00058237	CUB00058241	1988	Bush et al., "Daptomycin (LY146032) Treatment of Experimental Enterococcal Endocarditis," Antimicrobial Agents and Chemotherapy, 32(6):877-881	
478	CUB00145070	CUB00145073	1989	Kennedy and Chambers, "Daptomycin (LY146032) for Prevention and Treatment of Experimental Aortic Valve Endocarditis in Rabbits," Antimicrobial Agents and Chemotherapy, 33(9):1522-1525	I
479	CUB00063153	CUB00063156	1989	Mader and Adams, "Comparative Evaluation of Daptomycin (LY146032) and Vancomycin in the Treatment of Experimental Methicillin-Resistant Staphylococcus aureus Osteomyelitis in Rabbits," Antimicrobial Agents and Chemotherapy, 33(5):689-692	I
480	BER000550	BER000557		[REDACTED]	I, A, H
481	BER000421	BER000422		[REDACTED]	I, A, H
482	BER000776	BER000785	11/4/1999	[REDACTED]	I, A, H
483	BER000712	BER000743	12/10/1999	[REDACTED]	I, A, H
484	BER000746	BER000775	10/11/2000	[REDACTED]	I, A, H
485	BER000826	BER000855	12/13/1999	[REDACTED]	I, A, H